Mahalia S. Desruisseaux, MD
Associate Professor of Medicine (Infectious Diseases)Cards
Appointments
Additional Titles
Affiliated Faculty, Yale Institute for Global Health
Contact Info
Appointments
Additional Titles
Affiliated Faculty, Yale Institute for Global Health
Contact Info
Appointments
Additional Titles
Affiliated Faculty, Yale Institute for Global Health
Contact Info
About
Titles
Associate Professor of Medicine (Infectious Diseases)
Affiliated Faculty, Yale Institute for Global HealthAppointments
Infectious Diseases
Associate Professor on TermPrimary
Other Departments & Organizations
Education & Training
- Research Fellow, Neuroscience
- Albert Einstein College of Medicine (2008)
- Fellow, Infectious Diseases
- Albert Einstein College of Medicine/ Montefiore Medical Center (2007)
- Resident, Internal Medicine
- North Shore University Hospital - Hofstra/Northwell (2003)
- MD
- Rutgers Robert Wood Johnson Medical School
- BA
- Queens College - City University of New York
Research
Overview
The Desruisseaux laboratory works on cerebral malaria, a disease in which > 25% of survivors suffer from persistent neurological and cognitive deficits, despite successful anti-parasitic treatment. The goal of the laboratory is to identify the factors that cause these adverse long-term neurological sequelae.
The Desruisseaux lab has been particularly interested in the aberrant regulation of cerebral vascular tone, inflammation, blood-brain barrier disturbances, and eventually neuronal and glial degeneration after plasmodial infection, using a mouse model of experimental cerebral malaria. Our focus is on alterations in the synthesis and activation of vasomodulatory compounds during parasitic disease, and the effects of these alterations on cerebral perfusion, inflammation and blood-brain barrier disruption, and ultimately on gliopathy, neuronal damage and long-term neurological deficits. We identified endothelin-1, a potent vasoactive peptide with mitogenic and pro-inflammatory properties, as a key contributor to endothelial remodeling, neuroinflammation, long-term neurological damage and mortality during cerebral malaria. We also demonstrated that tau protein, a protein important in the formation of neurofibrillary tangles in neurodegenerative diseases, is abnormally regulated in our experimental model, demonstrating that long term sequelae are the result of potentially reversible vascular, biochemical and physiological changes in brains of infected mice.
In collaboration with investigators at the University of Malawi College of Medicine in Blantyre Malawi and at Indiana University, our laboratory will study the mechanisms of the disease process in pediatric patients from malaria endemic regions to test the translatability of our findings in the experimental model and to potentially derive novel therapeutic targets.
Medical Subject Headings (MeSH)
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Sheela Shenoi, MD, MPH, FIDSA
Jeanne Hendrickson, MD
Neima Briggs, MD, PhD
Albert C Shaw, MD, PhD
Alessandro Santin, MD
Brinda Emu, MD
Malaria, Cerebral
Chagas Disease
Blood-Brain Barrier
Endothelins
Publications
2023
COVID-19 Convalescent Plasma Therapy: Long-term Implications
Yoon H, Li Y, Goldfeld K, Cobb G, Sturm-Reganato C, Ostrosky-Zeichner L, Jayaweera D, Philley J, Desruisseaux M, Keller M, Hochman J, Pirofski L, Ortigoza M, Hochman J, Cronstein B, Keeling D, Rappoport N, Saraga J, Holahan J, Ortigoza M, Pirofski L, Yoon H, Sturm-Reganato C, Cobb G, Andela R, Darwish Y, Taveras M, Xin P, LaFleur J, Cleare L, Goldfeld K, Li Y, Ortigoza M, O'Keeffe M, Cobb G, Sturm-Reganato C, Rahman F, Ajayi A, Rodriguez S, Iturrate E, Gallagher J, Thomas O, Ramos D, Fong C, Pirofski L, Yoon H, Keller M, Asencio A, Eke I, Castro J, Shan J, Chalco A, LaFleur J, Cleare L, Desruisseaux M, Cortezzo G, Rocco E, Ndunge O, Parmelee C, Solomon G, Cahil S, Jayaweera D, Lee C, Ransford D, Dasmany D, Corona A, Moreno K, Martinez G, Otero C, McPherson D, Ostrosky-Zeichner L, Patel B, Nigo M, Huebinger R, Dronavalli G, Grimes C, Umana V, Hernandez M, Nielsen L, Stutz T, Mammadova M, Dentino A, Heath T, Martin J, Bello F, Hinojosa E, Philley J, Devine M, Hibbard R, Ford A. COVID-19 Convalescent Plasma Therapy: Long-term Implications. Open Forum Infectious Diseases 2023, 11: ofad686. PMID: 38269049, PMCID: PMC10807994, DOI: 10.1093/ofid/ofad686.Peer-Reviewed Original ResearchAltmetricConceptsPost-acute sequelaePROMIS scoresCOVID-19 convalescent plasma (CCP) therapySARS-CoV-2 infection symptomsSARS-CoV-2 infectionAcute COVID-19Convalescent plasma therapyGlobal health assessmentPhysical health scoresCOVID-19 hospitalizationCOVID-19 trialsSelf-reported symptomsRespective reference groupsRace/ethnicityPASC symptomsRandomization armAcute infectionAcute treatmentPlasma therapyGeneral symptomsSymptom SurveyLong-term effectsHealth scoresOverall healthDisease severityEffects of anti‐tau immunotherapy on reactive microgliosis, cerebral endotheliopathy, and cognitive function in an experimental model of cerebral malaria
Ndunge O, Shikani H, Dai M, Freeman B, Desruisseaux M. Effects of anti‐tau immunotherapy on reactive microgliosis, cerebral endotheliopathy, and cognitive function in an experimental model of cerebral malaria. Journal Of Neurochemistry 2023, 167: 441-460. PMID: 37814468, PMCID: PMC10596299, DOI: 10.1111/jnc.15972.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsNeural cell injuryCerebral malariaExperimental CMCell injuryUninfected micePHF-1Cell activationNeurodegenerative diseasesAbnormal regulationExperimental modelAnti-tau immunotherapyTau-targeting therapiesExperimental cerebral malariaGlial cell activationPlasmodium berghei ANKAPlasmodium berghei NK65Abnormal tau phosphorylationSubsequent neurocognitive impairmentSignificant memory impairmentNeural cell damageMicrovascular congestionPbA infectionInflammatory markersBerghei ANKANeurological deficitsIntegrated Care Models: HIV and Substance Use
Hill K, Kuo I, Shenoi S, Desruisseaux M, Springer S. Integrated Care Models: HIV and Substance Use. Current HIV/AIDS Reports 2023, 20: 286-295. PMID: 37698755, PMCID: PMC11034717, DOI: 10.1007/s11904-023-00667-9.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsSubstance use disordersUse disordersSubstance useIntegrated careRecent HIV outbreaksHIV viral suppressionMultidisciplinary care teamHIV virologic suppressionOpioid use disorderRisk of HIVHarm reduction programsSubstance use treatmentEvidence-based strategiesVirologic suppressionViral suppressionHIV outbreakCare teamProvider trainingHIVOnward transmissionHealth outcomesCare servicesClinic leadershipCare integrationMedical literatureBuilding an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center's Experience and Reflections
Gleeson S, Zapata H, Bathgate M, Emu B, Frederick J, Friedland G, Golden M, Meyer J, Radin J, Sideleau R, Shaw A, Shenoi S, Trubin P, Virata M, Barakat L, Desruisseaux M. Building an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center's Experience and Reflections. Clinical Infectious Diseases 2023, 77: 703-710. PMID: 37078888, DOI: 10.1093/cid/ciad236.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsEducational activitiesHealthcare inequitiesInfectious Diseases SectionSingle-center experienceCoronavirus disease 2019 (COVID-19) pandemicDisease 2019 pandemicMixed-methods assessmentLearning objectivesPilot curriculumEducational trainingCurriculumCenter experienceLong-term behavioral changesProgram outcomesDisease sectionDisease diversityPhysician perspectivesResponse rateHealth disparitiesYale SchoolInequitiesAntiracismBehavioral changesRacismEquity
2022
Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients
Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, Li Y, Wu D, Cobb GF, Baptiste G, O’Keeffe M, Corpuz MO, Ostrosky-Zeichner L, Amin A, Zacharioudakis IM, Jayaweera DT, Wu Y, Philley JV, Devine MS, Desruisseaux MS, Santin AD, Anjan S, Mathew R, Patel B, Nigo M, Upadhyay R, Kupferman T, Dentino AN, Nanchal R, Merlo CA, Hager DN, Chandran K, Lai JR, Rivera J, Bikash CR, Lasso G, Hilbert TP, Paroder M, Asencio AA, Liu M, Petkova E, Bragat A, Shaker R, McPherson DD, Sacco RL, Keller MJ, Grudzen CR, Hochman JS, Pirofski LA, Rahman F, Ajayi A, Rodriguez S, Ledesma A, Keeling D, Rappoport N, Ebel S, Kim J, Chang M, Chan K, Patel P, Martocci A, Dave S, Darwish Y, Taveras M, Shoyelu V, Xin P, Iturrate E, Moldolsky L, Raimondo B, Mendez S, Hughes P, Sterling S, Lord A, Yaghi S, Veloso K, Sheikh M, Visconti-Ferrara E, Fleming A, Youn H, Jane Fran B, Medina R, McKell R, Khan S, Hamilton T, Sanchez C, Patel N, Cleare L, Vergnolle O, Nakouzi A, Quevedo G, Bortz R, Wirchnianski A, Florez C, Babb R, Ayala J, Tsagaris K, James A, Eke I, Obeidallah A, Sandu O, Sohval S, Serrano-Rahman L, Uehlinger J, Bartash R, Al-Abduladheem A, Gendlina I, Sheridan C, Bortnick A, Eichler J, Kaufman R, Yukelis S, Pennock M, Goggin M, Shen C, Annam J, Khokhar A, Barboto D, Lally B, Lee A, Lee M, Yang X, Allen S, Malaviya A, Moussa O, Park R, Sample R, Bae A, Benoni G, Boerger L, Baker L, Luther M, Ameti L, Briggs N, Golden M, Gormally M, Huang G, Johnson R, Morrison A, Montagna-Hill M, Rivera B, Cortezzo G, Debski K, Nicoletti, DeBenedictis K, Davis R, Marshall C, Duque Cuartas M, Beauchamps L, Bertran-Lopez J, Gonzales Zamora J, Delgado-Lelievre M, Dominguez S, Lee C, Kusack H, Karakeshishyan V, Hajaz A, Deniz D, Garcia G, Dae K, Blenet P, Jaffe D, Olson L, Sabogal D, Blust O, Del Prete Perez V, Bornia C, Rodriguez-Perez V, Calderon V, Ramdev R, Jolly A, Guzman I, Guerra R, Brito S, Hobbs R, Denham R, Dick J, Hernandez M, Nielsen L, Anjum S, Mader S, Stutz T, Mammadova M, Nichols P, Khan T, Boktour M, Castaneda B, Benitez B, Hinojosa E, Guerra B, Ortiz A, Hebbeler-Clark R, McShane P, Hibbard R, Hawkins B, Dohanich E, Wadle C, Greenlee K, Brooks J, Herrick C, Gode A, Bergl P, Hu K, Patel J, Srinivasan S, Graf J, Klis C, Reimer K, Carpenter E, Naczek C, Petersen R, Dex R, Drossart J, Zelten J, Brummitt C, Liang M, Yanny L, Dennison G, Runningen P, Brzezinski B, Fiebig S, Naczek C, Kasdorf M, Parameswaran L, Corcoran A, Rohatgi A, Wronska M, Wu X, Srinivasan R, Deng F, Filardo T, Pendse J, Blaser S, Whyte O, Gallagher J, Thomas O, Ramos D, Sturm-Reganato C, Fong C, Daus I, Payoen A, Chiofolo J, Friedman M, Wu D, Jacobson J, Schneider J, Sarwar U, Wang H, Huebinger R, Dronavalli G, Bai Y, Grimes C, Eldin K, Umana V, Martin J, Heath T, Bello F, Ransford D, Laurent-Rolle M, Shenoi S, Akide-Ndunge O, Thapa B, Peterson J, Knauf K, Patel S, Cheney L, Tormey C, Hendrickson J. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients. JAMA Internal Medicine 2022, 182: 115-126. PMID: 34901997, PMCID: PMC8669605, DOI: 10.1001/jamainternmed.2021.6850.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCCP recipientsPlacebo recipientsSecondary outcomesSymptom durationHospitalized patientsPrimary outcomeDay 28COVID-19SARS-CoV-2 serostatusSARS-CoV-2 titersWorld Health Organization (WHO) ordinal scaleCOVID-19 convalescent plasmaConvalescent plasma usePlacebo-controlled trialLess daysExploratory subgroup analysisNon-Hispanic blacksSARS-CoV-2CCP efficacyConcomitant medicationsAdverse eventsClinical improvementSymptom onsetConvalescent plasmaMedian age
2021
Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19
Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, Laurent-Rolle M, Deng Y, Hendrickson JE, Tormey CA, Desruisseaux MS. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLOS ONE 2021, 16: e0254453. PMID: 34320004, PMCID: PMC8318280, DOI: 10.1371/journal.pone.0254453.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsCOVID-19 convalescent plasmaSevere COVID-19Convalescent plasmaPlasma recipientsHospital mortalityUnexposed cohortCCP administrationSevere COVID-19 infectionPropensity score-matched analysisCOVID-19Limited therapeutic optionsCOVID-19 infectionCoronavirus disease 2019CCP recipientsHospital stayPrimary endpointSecondary endpointsHospital daysHospital dischargeEarly administrationComplete followMechanical ventilationTherapeutic optionsClinical differencesSevere disease
2020
Inclusion, Diversity, Access, and Equity (IDA&E) Roadmap: Infectious Diseases Society of America’s Commitment to the Future
Desruisseaux MS, Tan TQ. Inclusion, Diversity, Access, and Equity (IDA&E) Roadmap: Infectious Diseases Society of America’s Commitment to the Future. The Journal Of Infectious Diseases 2020, 222: s523-s527. PMID: 32926738, DOI: 10.1093/infdis/jiaa153.Commentaries, Editorials and LettersCitations
2019
Captain Herbert B. Tanowitz, M.D., F.I.D.S.A., F.A.C.P., F.R.S.T.M.H., 1941–2018
Desruisseaux M, Engman D. Captain Herbert B. Tanowitz, M.D., F.I.D.S.A., F.A.C.P., F.R.S.T.M.H., 1941–2018. American Journal Of Pathology 2019, 189: 2-3. DOI: 10.1016/j.ajpath.2018.10.003.Commentaries, Editorials and Letters
2018
Endothelins in inflammatory neurological diseases
D'Orléans-Juste P, Akide Ndunge O, Desbiens L, Tanowitz HB, Desruisseaux MS. Endothelins in inflammatory neurological diseases. Pharmacology & Therapeutics 2018, 194: 145-160. PMID: 30291906, PMCID: PMC6348026, DOI: 10.1016/j.pharmthera.2018.10.001.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricMeSH Keywords and ConceptsConceptsCentral nervous systemNeuroinflammatory processesCentral nervous system vasculitisNon-infectious inflammatory processesBlood-brain barrier levelEndothelin-1 antagonistsSynthesis of endothelinInflammatory neurological diseasesMediator/modulatorProgression of neurodegenerationPotent vasoactive compoundsNeuroinflammatory diseasesEndothelin pathwayEndothelin-1Inflammatory processClinical trialsVasoactive compoundsCardiovascular propertiesNervous systemAmino acid peptideNeurological diseasesEndothelial integrityEndothelinAlzheimer's diseaseNeurodegenerative disordersTrypanosoma cruzi Produces the Specialized Proresolving Mediators Resolvin D1, Resolvin D5, and Resolvin E2
Colas RA, Ashton AW, Mukherjee S, Dalli J, Akide-Ndunge OB, Huang H, Desruisseaux MS, Guan F, Jelicks LA, dos Santos F, Nagajyothi J, Zingman MA, Reyes J, Weiss LM, Serhan CN, Tanowitz HB. Trypanosoma cruzi Produces the Specialized Proresolving Mediators Resolvin D1, Resolvin D5, and Resolvin E2. Infection And Immunity 2018, 86: e00688-17. PMID: 29358332, PMCID: PMC5865043, DOI: 10.1128/iai.00688-17.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsEnzyme-linked immunosorbent assayResolvin D1Chagas diseaseMediators of inflammationCD-1 miceRvD1 levelsChronic cardiomyopathyAcute myocarditisMyocardial inflammationProinflammatory eicosanoidsProresolving mediatorsChronic phasePathological featuresPlasma levelsLifelong infectionLipid mediatorsResolvin D5Host responseHuman infectionsBacterial infectionsRvD1InflammationInfectionImmunosorbent assayElevated levels
Academic Achievements and Community Involvement
activity President
Professional OrganizationsAmerican Society of Tropical Medicine and HygienePresident, American Committee of Molecular, Cellular and ImmunoparasitologyDetails11/22/2019 - Presentactivity Board Member
CommitteesYale School of MedicineExecutive Committee, Department of Internal Medicine Diversity CommitteeDetails02/25/2019 - Presentactivity Committee Member
Professional OrganizationsInfectious Diseases Society of AmericaMember, Research CommitteeDetails10/07/2019 - Presentactivity Committee Member
Professional OrganizationsInfectious Diseases Society of AmericaMentoring Workgroup Subcommittee, IDSA Medical Education Community of PracticeDetails10/07/2019 - Presenthonor Bailey K. Ashford Medal
National AwardAmerican Society of Tropical Medicine and HygieneDetails11/15/2020United States
Clinical Care
Overview
Clinical Specialties
Board Certifications
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Latest Certification Date
- 2021
- Original Certification Date
- 2003
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- March 15, 2024
Announcing the New Residents in the Yale-Waterbury Internal Medicine Residency Program!
- March 15, 2024
Announcing the Incoming Residents in the Internal Medicine Traditional Residency Program!
- January 30, 2024
Fostering Equity and Inclusion in Infectious Diseases at Yale
- November 20, 2023
Fellow Focus in Four: Neima Briggs, MD, PhD, Infectious Diseases
Get In Touch
Contacts
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.